Published in Blood on July 25, 2011
Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice. Blood (2015) 1.43
Common genetic risk factors for venous thrombosis in the Chinese population. Am J Hum Genet (2013) 1.01
The role of thrombomodulin lectin-like domain in inflammation. J Biomed Sci (2012) 1.00
Tissue factor and cancer. Thromb Res (2012) 0.95
Endothelial cell protein C receptor opposes mesothelioma growth driven by tissue factor. Cancer Res (2013) 0.91
Cancer cells induced to express mesenchymal phenotype release exosome-like extracellular vesicles carrying tissue factor. J Biol Chem (2012) 0.91
Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond. J Mol Med (Berl) (2013) 0.90
Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice. J Thromb Haemost (2014) 0.88
Thrombin drives tumorigenesis in colitis-associated colon cancer. Cancer Res (2014) 0.84
Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen. Cancer Res (2015) 0.82
Investigation of the essential role of platelet-tumor cell interactions in metastasis progression using an agent-based model. Theor Biol Med Model (2014) 0.82
Protease-activated receptors (PARs)-biology and role in cancer invasion and metastasis. Cancer Metastasis Rev (2015) 0.80
Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis. Onco Targets Ther (2016) 0.80
Role of the protein C receptor in cancer progression. Thromb Res (2014) 0.79
D-dimer: not just an indicator of venous thrombosis but a predictor of asymptomatic hematogenous metastasis in gastric cancer patients. PLoS One (2014) 0.78
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis. Carcinogenesis (2015) 0.78
Thrombomodulin expression regulates tumorigenesis in bladder cancer. BMC Cancer (2014) 0.76
D-dimer is an essential accompaniment of circulating tumor cells in gastric cancer. BMC Cancer (2017) 0.75
Thrombomodulin modulates cell migration in human melanoma cell lines. Melanoma Res (2014) 0.75
Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis. BMC Cancer (2016) 0.75
A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality. Oncologist (2016) 0.75
Targeting clotting proteins in cancer therapy - progress and challenges. Thromb Res (2016) 0.75
The cytoprotective protein C pathway. Blood (2006) 5.75
Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst (1970) 4.88
Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood (2004) 3.13
The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest (2005) 2.80
Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood (2000) 2.78
Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood (2004) 2.45
Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol (2004) 2.18
Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood (2010) 2.14
Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell (2006) 2.08
A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest (1998) 2.08
Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta. J Cell Biol (1985) 1.92
Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res (2002) 1.64
Thrombomodulin. J Thromb Haemost (2003) 1.60
Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci U S A (1995) 1.58
The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost (2006) 1.28
Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1-mediated vascular endothelial barrier enhancement. Blood (2009) 1.23
Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin Thromb Hemost (2008) 1.17
Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain. Blood (2008) 1.11
Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood (2008) 1.11
Role of activated protein C and its receptor in inhibition of tumor metastasis. Blood (2009) 1.09
Preparation of monoclonal antibodies to murine platelet glycoprotein IIb/IIIa (alphaIIbbeta3) and other proteins from hamster-mouse interspecies hybridomas. Biochem Biophys Res Commun (1999) 1.05
Novel functions of thrombomodulin in inflammation. Crit Care Med (2004) 1.01
Mouse models of thrombosis: thrombomodulin. Thromb Haemost (2004) 1.00
Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency. Blood (2003) 0.97
Thrombomodulin modulates growth of tumor cells independent of its anticoagulant activity. J Clin Invest (1998) 0.95
Knockdown of thrombomodulin enhances HCC cell migration through increase of ZEB1 and decrease of E-cadherin gene expression. Ann Surg Oncol (2010) 0.94
Haemostatic factors in human peripheral afferent lymph. Thromb Haemost (2000) 0.94
Inhibition of invasion and experimental metastasis of murine melanoma cells by human soluble thrombomodulin. Cancer Lett (2000) 0.90
A thrombomodulin mutation that impairs activated protein C generation results in uncontrolled lung inflammation during murine tuberculosis. Blood (2005) 0.88
Expression of thrombomodulin in squamous cell carcinoma of the lung: its relationship to lymph node metastasis and prognosis of the patients. Cancer Lett (2000) 0.87
The lectin-like domain of thrombomodulin protects against ischaemia-reperfusion lung injury. Eur Respir J (2008) 0.85
Prognostic significance of thrombomodulin expression and vascular invasion in stage I squamous cell carcinoma of the lung. Lung Cancer (2001) 0.85
Soluble thrombomodulin is antithrombotic in the presence of neutralising antibodies to protein C and reduces circulating activated protein C levels in primates. Br J Haematol (2006) 0.84
Thrombomodulin expression in colorectal carcinoma is protective and correlates with survival. Br J Cancer (2006) 0.83
The antimetastatic role of thrombomodulin expression in islet cell-derived tumors and its diagnostic value. Clin Cancer Res (2004) 0.82
Tumor growth and metastasis are not affected in thrombin-activatable fibrinolysis inhibitor-deficient mice. J Thromb Haemost (2004) 0.81
Thrombomodulin enhances the invasive activity of mouse mammary tumor cells. J Biochem (2005) 0.79
The role of thrombomodulin in malignancy. Semin Thromb Hemost (2007) 0.79
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab (2006) 12.41
Knockout rats via embryo microinjection of zinc-finger nucleases. Science (2009) 12.33
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology (2007) 4.83
Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med (2014) 4.58
Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest (2007) 3.88
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 3.82
Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest (2006) 3.75
Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med (2007) 3.35
Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med (2007) 3.35
Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci (2004) 3.31
Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med (2009) 3.24
Cerebral ischemia-hypoxia induces intravascular coagulation and autophagy. Am J Pathol (2006) 3.18
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med (2003) 3.17
Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood (2004) 3.13
Antisense transcripts are targets for activating small RNAs. Nat Struct Mol Biol (2008) 3.02
Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest (2006) 3.00
Restricted inactivation of serum response factor to the cardiovascular system. Proc Natl Acad Sci U S A (2004) 2.98
Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest (2004) 2.57
Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem (2007) 2.55
Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion. PLoS Biol (2006) 2.35
The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance. Cell Metab (2009) 2.35
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology (2005) 2.25
Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol (2004) 2.18
The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med (2007) 2.16
Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood (2010) 2.14
Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance. J Clin Invest (2006) 2.13
Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model. J Pathol (2014) 2.02
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res (2007) 1.99
Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res (2006) 1.98
The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med (2003) 1.98
Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest (2004) 1.93
Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes (2002) 1.91
SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic rats. Proc Natl Acad Sci U S A (2009) 1.89
Nuclear receptors Nur77, Nurr1, and NOR-1 expressed in atherosclerotic lesion macrophages reduce lipid loading and inflammatory responses. Arterioscler Thromb Vasc Biol (2006) 1.87
A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nat Med (2005) 1.85
Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest (2004) 1.83
Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med (2003) 1.83
Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun (2012) 1.82
Fibrinogen triggers astrocyte scar formation by promoting the availability of active TGF-beta after vascular damage. J Neurosci (2010) 1.82
Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med (2006) 1.82
Fibrinogen is required for maintenance of platelet intracellular and cell-surface P-selectin expression. Blood (2009) 1.79
Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol (2005) 1.77
Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Mol Cell Biol (2004) 1.75
PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci U S A (2002) 1.73
Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway. Genes Dev (2008) 1.73
The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A. Blood (2011) 1.71
Fibrinogen, acting as a mitogen for tubulointerstitial fibroblasts, promotes renal fibrosis. Kidney Int (2011) 1.70
Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J Clin Invest (2006) 1.69
Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. Nucleic Acids Res (2003) 1.68
Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes (2004) 1.65
Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res (2002) 1.64
Fibrinogen alpha and gamma genes and factor VLeiden in children with thromboembolism: results from 2 family-based association studies. Blood (2009) 1.62
Coagulation and innate immune responses: can we view them separately? Blood (2009) 1.61
Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. Am J Respir Crit Care Med (2005) 1.60
Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice. Crit Care Med (2006) 1.60
Low molecular weight heparin attenuates multiple organ failure in a murine model of disseminated intravascular coagulation. Crit Care Med (2005) 1.58
Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. Nat Med (2012) 1.58
Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J Clin Invest (2005) 1.55
Gene expression profiling identifies C/EBPdelta as a candidate regulator of endotoxin-induced disseminated intravascular coagulation. Am J Respir Crit Care Med (2007) 1.54
Antisense therapy for cancer. Nat Rev Cancer (2005) 1.54
Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest (2007) 1.52
Helium/oxygen-driven albuterol nebulization in the management of children with status asthmaticus: a randomized, placebo-controlled trial. Pediatr Crit Care Med (2010) 1.48
Caveolin-1-dependent apoptosis induced by fibrin degradation products. Blood (2008) 1.47
Survivin splice variants regulate the balance between proliferation and cell death. Oncogene (2005) 1.46
Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells. Cancer Biol Ther (2006) 1.46
Essential role for survivin in early brain development. J Neurosci (2005) 1.44
Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice. J Clin Invest (2013) 1.44
Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest (2010) 1.41
Therapeutic potential for microRNAs. Adv Drug Deliv Rev (2007) 1.41
Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol (2006) 1.40
Calsarcin-2 deficiency increases exercise capacity in mice through calcineurin/NFAT activation. J Clin Invest (2008) 1.40
Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood (2009) 1.36
Retracted Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality. Blood (2009) 1.36
Severe impairment in liver insulin signaling fails to alter hepatic insulin action in conscious mice. J Clin Invest (2005) 1.35
Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood (2003) 1.35
Prevention of hepatic steatosis and hepatic insulin resistance by knockdown of cAMP response element-binding protein. Cell Metab (2009) 1.31
Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol (2013) 1.30
Deficiency of adiponectin receptor 2 reduces diet-induced insulin resistance but promotes type 2 diabetes. Endocrinology (2006) 1.29
mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome. J Clin Oncol (2010) 1.29
Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood (2012) 1.26